ClinicalTrials.gg
CompletedNCT02527109Updated Oct 23, 2018

The Effect of Intra-anal Nifedipine, Used As Add-on to Conservative Therapy, on Pain in Patients With Anal Fissure

A Phase 2/3 interventional study of Nifedipine in Chronic Anal Fissure, sponsored by RDD Pharma Ltd. Completed at 24 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-10-23.

Sponsored by RDD Pharma Ltd · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
339
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of the study is to examine the effect of Nifedipine, applied intra-anally through our drug delivery device, on rectal pain severity in anal fissure patients that are being managed with conservative treatment.

Read the detailed description

This is a randomized, double-blinded study. All patients in the study will be treated with the conservative standard of care for anal fissure. Study medication will be used as an add-on to conservative therapy, and will consist of 3 groups:

  1. Treatment Group 1- 12 mg of Nifedipine to be self-administered twice daily.
  2. Treatment Group 2- 12 mg of Nifedipine to be self-administered once daily in the morning hours and placebo to be self-administered in the evening.
  3. Placebo Group - Placebo to be self-administered twice daily. Approximately 330 subjects will participate in this study. A screening visit will be used to determine subject suitability for inclusion in the trial. Within one week of the screening visit, subjects who meet all inclusion criteria and none of the exclusion criteria will receive either Nifedipine 12 mg X2 a day (BID) (24 mg/day total) or Nifedipine 12 mg X1/day to be administered in the morning hours and a matching placebo X1/day to be administered in the evening hours (12 mg/day total) or a matching placebo X2 a day (BID) (0 mg/day total) for a period of 8 weeks. During this period, 4 study visits (at 0, 2, 5, and 8 weeks) will take place. Study medication and placebo will be administered BID (in the morning and in the evening). In addition to receiving study medication, subjects will be maintained on a conservative standard treatment for Anal Fissure: sitz baths, high fiber diet, stool softeners and plenty of fluids.

Upon completion of the treatment cycle, patients will be contacted by phone (at weeks 10, 13 and 16) and will be questioned about recurrent symptoms e.g. pain or bleeding.

Patients that:

  1. Were enrolled to one of the investigational groups ,and completed the 8 weeks treatment period or discontinued treatment because the investigator deemed them as healed AND
  2. Experience symptoms of recurrence AND ARE
  3. Willing to participate in an open label extension will receive Nifedipine 12 mg X2 a day (BID) for a period of 8 weeks. During this period, 4 study visits (at 0, 2, 5, and 8 weeks from the start of retreatment) will take place.
02

Conditions studied

  • Chronic Anal Fissure

Browse trials for

03

In context

Fissure in Ano

84 studies on the registry are indexed under Fissure in Ano; 16 are open to participants now.

This study's enrollment of 339 is above the median of 99 across 65 interventional studies indexed under Fissure in Ano.

Browse Fissure in Ano studies →

Lead sponsor

RDD Pharma Ltd is the lead sponsor of 11 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects meeting the following criteria will be eligible to participate in the trial:
  1. Single anal fissure;
  2. Signed written ;
  3. Male or female subjects 18 to 65 years of age inclusive;
  4. Has chronic anal fissure defined as history of rectal pain at least three days a week for at least 6 weeks - or more AND at least one of the following:

    • Sentinel skin tag
    • Hypertrophied anal papilla
    • Exposure of the underlying internal anal sphincter
    • Anal cicatrisation
  5. Visual analogue scale of average 24 hours rectal pain (VAS) of > 40 mm in screening visit
  6. Capable of using the IVRS and able to adequately communicate comprehension of the IVRS questions to the investigator
  7. If female, is non-lactating, has a negative urine pregnancy test result, and does not plan on becoming pregnant during the study, or not of (hysterectomy or tubal ligation at least 6 months prior to entry to the study or for 1 year); if of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice or be willing to continue to practice acceptable from screening and until 1 week after the study medication has been discontinued.

Acceptable birth control includes :

  • combined (estrogen and progestogen containing) hormonal contraception
  • associated with inhibition of ovulation; oral OR intravaginal OR transdermal.
  • progestogen-only hormonal contraception associated with inhibition of ovulation: oral OR injectable OR implantable.
  • progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action
  • intrauterine device (IUD)
  • intrauterine hormone-releasing system ( IUS)
  • bilateral tubal occlusion
  • vasectomised partner
  • sexual abstinence
  • male or female condom with or without spermicide
  • cap, diaphragm or sponge with spermicide

Exclusion criteria

Exclusion Criteria:

  • Subjects are excluded from participation in the study if any of the following criteria apply:

    1. Known allergy to Nifedipine
    2. Unwilling to stop all other concomitant topical preparations applied in and around the anus from screening through the end of the study
    3. Subfissure injection of botulinum toxin in the 3 months prior to screening.
    4. Fissure resulting from inflammatory bowel disease, venereal disease, perianal psoriasis, immunodeficiency syndrome
    5. Atypical fissure (occurs off the midline) in which secondary causes were not excluded.
    6. Deemed by the investigator as anal fissure for which surgery is indicated
    7. Anal abscess;
    8. Grade 4 hemorrhoids
    9. Fixed anal stenosis
    10. Active or past history of cardiovascular or cerebrovascular disease including but not limited to angina pectoris, myocardial infarction, /stroke, arrhythmia or ecg changes that requires medical treatment or deemed by the investigator as , moderate to severe congestive heart failure, or cardiac valve abnormalities;
    11. Type 1 diabetes mellitus
    12. Insulin treated type 2 diabetes mellitus
    13. Renal failure defined as a serum creatinine > 1.5 mg/dL (133 µmol/L) at screening
    14. Liver disease defined as (AST) or alanine aminotransferase(ALT) >2 X at screening
    15. Malignant disease within 3 years of screening
    16. Has uncontrolled hypertension (sitting blood pressure >160/95 mmHg at screening)
    17. Has hypotension (blood pressure lower than 90/60 mm Hg at screening)
    18. History of chronic gastrointestinal disease such as Crohn's disease or ulcerative colitis
    19. History of major rectal surgery
    20. History of , ,
    21. Has clinical laboratory test values (chemistry, hematology, or urinalysis) judged to be clinically significant by the investigator at screening;
    22. Has used, in the last two weeks, drugs that may affect blood coagulation, such as Aspirin at a dose higher than 500 mg/day, Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine Rivaroxaban, Apixaban, Edoxaban
    23. Is treated with drugs that may affect the anal sphincter:

      1. Calcium channel blockers such as Nifedipine, Diltiazem or Verapamil
      2. Nitroglycerin or nitrates
    24. Has, upon physical examination, a rectal deformation or signs of rectal disease such as fistula, infection or space occupying lesion;
    25. Participated in a clinical study in the last 30 days prior to screening.
    26. Is an immediate family member of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site; or is employed or related to the Sponsor, CRO or investigator;
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
339 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Intra-anal placebo administered BID.

    Drug: Nifedipine

  • Experimental
    Nifedipine 12 mg/day

    Intra-anal Nifedipine 12 mg administered OD.

    Drug: Nifedipine

  • Experimental
    Nifedipine 24 mg/day

    Intra-anal Nifedipine 12 mg administered BID.

    Drug: Nifedipine

Interventions

06

What researchers measure

Primary outcomes

  1. Rectal pain and measured by VAS

    Time frame: measured at day 56

Secondary outcomes

  1. Healing of anal fissure

    Healing is defined by lack of pain AND evidence of epithelization in a physical examination

    Time frame: day 56

07

Study locations

24 sites
  • UMHAT "Sveti Georgi", Internal Consulting Department
    Plovdiv, Bulgaria
  • "Multiprofile Hospital for Active Treatment - Doverie" AD, Clinic of Gastroenterology
    Sofia, 1632, Bulgaria
  • II MHAT, Internal Clinic, Department of Gastroenterology
    Sofia, Bulgaria
  • MC Health BG EOOD
    Sofia, Bulgaria
  • Multiprofile Hospital for Active Treatment Lulin
    Sofia, Bulgaria
  • MC "New rehabilitation centre'' EOOD
    Stara Zagora, Bulgaria
  • "Multiprofile Regional Hospital for Active Treatment - Dr. St. Cherkezov" AD Department of Gastroenterology
    Veliko Tarnovo, 5002, Bulgaria
  • IMSP Spitalul Clinic Municipal Nr 1
    Chisinau, Moldova, Republic of
  • IMSP Spitalul Clinic Municipal Nr 3 "Sfanta Treime"
    Chisinau, Moldova, Republic of
  • IMSP Spitalul Clinic Republican
    Chisinau, Moldova, Republic of
  • Med-Gastr Centrum Medyczne
    Lodz, 91-034, Poland
  • Ambulatorium Medyczne Medical Hair & Esthetic
    Lublin, 20-844, Poland
  • Centrum Innowacyjnych Terapii Sp. z o.o. Oddział w Piasecznie
    Piaseczno, 05-500, Poland
  • NZOZ Specjalistyczne Centrum Medyczne Flebo
    Wolomin, 05-200, Poland
  • Pelican Impex SRL
    Oradea, Jud. Bihor 410469, Romania
  • IRGH
    Cluj Napoca, Jud. Cluj 400162, Romania
  • Tvm Med Serv Srl
    Cluj Napoca, Jud. Cluj, Romania
  • Institutul Regional de Gastroenterologie si Hepatologie "Prof. Dr. Octavian Fodor"
    Cluj-Napoca, Jud. Cluj 400162, Romania
  • SC Schnelbach Medical Care SRL
    Ploiesti, Jud. Prahova, Romania
  • Spit. Clinic Judetean de Urgenta "Sf. Apostol Andrei" Constanta
    Constanta, Judet Constanta, Romania
  • Dacmed SRL
    Ploiesti, Judetul Prahova, Romania
  • Centrul Medical de Diagnostic si Tratament Ambulator Neomed SRL
    Brasov, 500283, Romania
  • Institutul Clinic Fundeni
    Bucharest, 022328, Romania
  • Centrul Medical Sfanta Vineri SRL
    Bucharest, Romania
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Jun 2018 and a completion of Aug 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2015
First posted
Aug 18, 2015
Start
May 2016
Primary completionActual
Jun 15, 2018
CompletionActual
Aug 22, 2018
Last update
Oct 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02527109
Lead sponsor
RDD Pharma Ltd
Responsible party
Sponsor
First posted
Aug 18, 2015
Start date
May 2016
Primary completion
Jun 15, 2018
Completion
Aug 22, 2018
Last update
Oct 23, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nifedipine

Start the discussion